Z160: Phase IIa started

Zalicus began a double-blind, placebo-controlled, U.S. Phase IIa trial to evaluate twice-daily 375 mg Z160 for 6 weeks in up to 140 patients with chronic neuropathic pain associated with lumbosacral radiculopathy. Zalicus expects to begin a second Phase IIa trial in patients with postherpetic neuralgia (PHN) next quarter and report top-line data from both trials in late 2H13. ...